Follow-Up Duration of Echocardiography in Patients with Kawasaki Disease with No Initial Coronary Aneurysms
To evaluate the optimal duration of echocardiographic follow-up in patients with Kawasaki disease without an initial coronary aneurysm. In this single-center, retrospective, observational study, we reviewed the results of follow-up echocardiography in children with Kawasaki disease enrolled in the P...
Gespeichert in:
Veröffentlicht in: | The Journal of pediatrics 2022-05, Vol.244, p.133-138.e1 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 138.e1 |
---|---|
container_issue | |
container_start_page | 133 |
container_title | The Journal of pediatrics |
container_volume | 244 |
creator | Wang, Qianzhi Morikawa, Yoshihiko Akahoshi, Shogo Miyata, Koichi Sakakibara, Hiroshi Matsushima, Takahiro Koyama, Yutaro Obonai, Toshimasa Kaneko, Tetsuji Miura, Masaru |
description | To evaluate the optimal duration of echocardiographic follow-up in patients with Kawasaki disease without an initial coronary aneurysm.
In this single-center, retrospective, observational study, we reviewed the results of follow-up echocardiography in children with Kawasaki disease enrolled in the Prospective Observational Study on Stratified Treatment with Immunoglobulin Plus Steroid Efficacy for Kawasaki Disease from a children's hospital. The main enrollment criterion was the absence of coronary aneurysms, defined as a maximum z-score (Zmax) ≥2.5, in the proximal right coronary artery and the proximal left anterior descending artery within 9 days from treatment initiation. The primary outcome was Zmax on follow-up echocardiography at up to 5 years.
Among 386 patients, 106 (27.5%) received prednisolone with intravenous immunoglobulin for first-line therapy, and 57 (14.8%) showed a poor response. Echocardiography at 1 month detected 9 patients with a Zmax ≥2, including 3 (0.8%) with coronary aneurysms requiring additional antithrombotic treatment and observation. Of 7 patients (1.8%) with normal echocardiographic findings at 1 month but a Zmax ≥2 later, 2 were lost to follow-up and 5 experienced spontaneous resolution, but none of the 7 patients required any change in management.
The optimal duration of echocardiographic follow-up may be 1 month in patients with no initial coronary aneurysms and a Zmax |
doi_str_mv | 10.1016/j.jpeds.2021.11.022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2600285140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347621010945</els_id><sourcerecordid>2600285140</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-38c42801d68d38d59c19aa0a4ea7f59b69ce0597a4102c63afd792e4383eda593</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhi1EBVvaX4CEfOSSMI7z5UMPaIEWFbU9lLM12BPWSzZO7YTV_vuaLnDsaaR33nc-HsZOBeQCRH2xztcj2ZgXUIhciByK4oAtBKgmq1spD9kCkpTJsqmP2ccY1wCgSoAjdpw01ULTLNjTje97v83uR341B5ycH7jv-LVZeYPBOv8YcFztuBv4r9SlYYp866YV_45bjPjk-JWLhJH26g_Pbwc3Oez50gc_YNjxy4HmsIub-Il96LCP9Pm1nrD7m-vfy2_Z3c-vt8vLu8zISk2ZbE1ZtCBs3VrZ2koZoRABS8Kmq9RDrQxBpRosBRSmltjZRhVUylaSxUrJE3a-nzsG_2emOOmNi4b6Hgfyc9RFncC0lSghWeXeaoKPMVCnx-A26WotQL9Q1mv9j7J-oayF0AlpSp29LpgfNmTfM29Yk-HL3kDpzWdHQUeT2BmyLpCZtPXuvwv-At1tj5c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2600285140</pqid></control><display><type>article</type><title>Follow-Up Duration of Echocardiography in Patients with Kawasaki Disease with No Initial Coronary Aneurysms</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wang, Qianzhi ; Morikawa, Yoshihiko ; Akahoshi, Shogo ; Miyata, Koichi ; Sakakibara, Hiroshi ; Matsushima, Takahiro ; Koyama, Yutaro ; Obonai, Toshimasa ; Kaneko, Tetsuji ; Miura, Masaru</creator><creatorcontrib>Wang, Qianzhi ; Morikawa, Yoshihiko ; Akahoshi, Shogo ; Miyata, Koichi ; Sakakibara, Hiroshi ; Matsushima, Takahiro ; Koyama, Yutaro ; Obonai, Toshimasa ; Kaneko, Tetsuji ; Miura, Masaru</creatorcontrib><description>To evaluate the optimal duration of echocardiographic follow-up in patients with Kawasaki disease without an initial coronary aneurysm.
In this single-center, retrospective, observational study, we reviewed the results of follow-up echocardiography in children with Kawasaki disease enrolled in the Prospective Observational Study on Stratified Treatment with Immunoglobulin Plus Steroid Efficacy for Kawasaki Disease from a children's hospital. The main enrollment criterion was the absence of coronary aneurysms, defined as a maximum z-score (Zmax) ≥2.5, in the proximal right coronary artery and the proximal left anterior descending artery within 9 days from treatment initiation. The primary outcome was Zmax on follow-up echocardiography at up to 5 years.
Among 386 patients, 106 (27.5%) received prednisolone with intravenous immunoglobulin for first-line therapy, and 57 (14.8%) showed a poor response. Echocardiography at 1 month detected 9 patients with a Zmax ≥2, including 3 (0.8%) with coronary aneurysms requiring additional antithrombotic treatment and observation. Of 7 patients (1.8%) with normal echocardiographic findings at 1 month but a Zmax ≥2 later, 2 were lost to follow-up and 5 experienced spontaneous resolution, but none of the 7 patients required any change in management.
The optimal duration of echocardiographic follow-up may be 1 month in patients with no initial coronary aneurysms and a Zmax <2 at 1 month. Coronary artery abnormalities observed after 1 month are rare and mostly benign in this category of patients.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/j.jpeds.2021.11.022</identifier><identifier>PMID: 34798077</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>American Heart Association ; Child ; Coronary Aneurysm - diagnostic imaging ; Coronary Aneurysm - etiology ; coronary artery lesion ; Coronary Vessels - diagnostic imaging ; Echocardiography ; Follow-Up Studies ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Infant ; Mucocutaneous Lymph Node Syndrome - complications ; Mucocutaneous Lymph Node Syndrome - diagnostic imaging ; Mucocutaneous Lymph Node Syndrome - drug therapy ; Retrospective Studies ; z-score</subject><ispartof>The Journal of pediatrics, 2022-05, Vol.244, p.133-138.e1</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-38c42801d68d38d59c19aa0a4ea7f59b69ce0597a4102c63afd792e4383eda593</citedby><cites>FETCH-LOGICAL-c359t-38c42801d68d38d59c19aa0a4ea7f59b69ce0597a4102c63afd792e4383eda593</cites><orcidid>0000-0003-1768-9927 ; 0000-0002-2049-5309 ; 0000-0003-3314-0571 ; 0000-0001-6041-1731</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022347621010945$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34798077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Qianzhi</creatorcontrib><creatorcontrib>Morikawa, Yoshihiko</creatorcontrib><creatorcontrib>Akahoshi, Shogo</creatorcontrib><creatorcontrib>Miyata, Koichi</creatorcontrib><creatorcontrib>Sakakibara, Hiroshi</creatorcontrib><creatorcontrib>Matsushima, Takahiro</creatorcontrib><creatorcontrib>Koyama, Yutaro</creatorcontrib><creatorcontrib>Obonai, Toshimasa</creatorcontrib><creatorcontrib>Kaneko, Tetsuji</creatorcontrib><creatorcontrib>Miura, Masaru</creatorcontrib><title>Follow-Up Duration of Echocardiography in Patients with Kawasaki Disease with No Initial Coronary Aneurysms</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>To evaluate the optimal duration of echocardiographic follow-up in patients with Kawasaki disease without an initial coronary aneurysm.
In this single-center, retrospective, observational study, we reviewed the results of follow-up echocardiography in children with Kawasaki disease enrolled in the Prospective Observational Study on Stratified Treatment with Immunoglobulin Plus Steroid Efficacy for Kawasaki Disease from a children's hospital. The main enrollment criterion was the absence of coronary aneurysms, defined as a maximum z-score (Zmax) ≥2.5, in the proximal right coronary artery and the proximal left anterior descending artery within 9 days from treatment initiation. The primary outcome was Zmax on follow-up echocardiography at up to 5 years.
Among 386 patients, 106 (27.5%) received prednisolone with intravenous immunoglobulin for first-line therapy, and 57 (14.8%) showed a poor response. Echocardiography at 1 month detected 9 patients with a Zmax ≥2, including 3 (0.8%) with coronary aneurysms requiring additional antithrombotic treatment and observation. Of 7 patients (1.8%) with normal echocardiographic findings at 1 month but a Zmax ≥2 later, 2 were lost to follow-up and 5 experienced spontaneous resolution, but none of the 7 patients required any change in management.
The optimal duration of echocardiographic follow-up may be 1 month in patients with no initial coronary aneurysms and a Zmax <2 at 1 month. Coronary artery abnormalities observed after 1 month are rare and mostly benign in this category of patients.</description><subject>American Heart Association</subject><subject>Child</subject><subject>Coronary Aneurysm - diagnostic imaging</subject><subject>Coronary Aneurysm - etiology</subject><subject>coronary artery lesion</subject><subject>Coronary Vessels - diagnostic imaging</subject><subject>Echocardiography</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Infant</subject><subject>Mucocutaneous Lymph Node Syndrome - complications</subject><subject>Mucocutaneous Lymph Node Syndrome - diagnostic imaging</subject><subject>Mucocutaneous Lymph Node Syndrome - drug therapy</subject><subject>Retrospective Studies</subject><subject>z-score</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P3DAQhi1EBVvaX4CEfOSSMI7z5UMPaIEWFbU9lLM12BPWSzZO7YTV_vuaLnDsaaR33nc-HsZOBeQCRH2xztcj2ZgXUIhciByK4oAtBKgmq1spD9kCkpTJsqmP2ccY1wCgSoAjdpw01ULTLNjTje97v83uR341B5ycH7jv-LVZeYPBOv8YcFztuBv4r9SlYYp866YV_45bjPjk-JWLhJH26g_Pbwc3Oez50gc_YNjxy4HmsIub-Il96LCP9Pm1nrD7m-vfy2_Z3c-vt8vLu8zISk2ZbE1ZtCBs3VrZ2koZoRABS8Kmq9RDrQxBpRosBRSmltjZRhVUylaSxUrJE3a-nzsG_2emOOmNi4b6Hgfyc9RFncC0lSghWeXeaoKPMVCnx-A26WotQL9Q1mv9j7J-oayF0AlpSp29LpgfNmTfM29Yk-HL3kDpzWdHQUeT2BmyLpCZtPXuvwv-At1tj5c</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Wang, Qianzhi</creator><creator>Morikawa, Yoshihiko</creator><creator>Akahoshi, Shogo</creator><creator>Miyata, Koichi</creator><creator>Sakakibara, Hiroshi</creator><creator>Matsushima, Takahiro</creator><creator>Koyama, Yutaro</creator><creator>Obonai, Toshimasa</creator><creator>Kaneko, Tetsuji</creator><creator>Miura, Masaru</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1768-9927</orcidid><orcidid>https://orcid.org/0000-0002-2049-5309</orcidid><orcidid>https://orcid.org/0000-0003-3314-0571</orcidid><orcidid>https://orcid.org/0000-0001-6041-1731</orcidid></search><sort><creationdate>20220501</creationdate><title>Follow-Up Duration of Echocardiography in Patients with Kawasaki Disease with No Initial Coronary Aneurysms</title><author>Wang, Qianzhi ; Morikawa, Yoshihiko ; Akahoshi, Shogo ; Miyata, Koichi ; Sakakibara, Hiroshi ; Matsushima, Takahiro ; Koyama, Yutaro ; Obonai, Toshimasa ; Kaneko, Tetsuji ; Miura, Masaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-38c42801d68d38d59c19aa0a4ea7f59b69ce0597a4102c63afd792e4383eda593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>American Heart Association</topic><topic>Child</topic><topic>Coronary Aneurysm - diagnostic imaging</topic><topic>Coronary Aneurysm - etiology</topic><topic>coronary artery lesion</topic><topic>Coronary Vessels - diagnostic imaging</topic><topic>Echocardiography</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Infant</topic><topic>Mucocutaneous Lymph Node Syndrome - complications</topic><topic>Mucocutaneous Lymph Node Syndrome - diagnostic imaging</topic><topic>Mucocutaneous Lymph Node Syndrome - drug therapy</topic><topic>Retrospective Studies</topic><topic>z-score</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Qianzhi</creatorcontrib><creatorcontrib>Morikawa, Yoshihiko</creatorcontrib><creatorcontrib>Akahoshi, Shogo</creatorcontrib><creatorcontrib>Miyata, Koichi</creatorcontrib><creatorcontrib>Sakakibara, Hiroshi</creatorcontrib><creatorcontrib>Matsushima, Takahiro</creatorcontrib><creatorcontrib>Koyama, Yutaro</creatorcontrib><creatorcontrib>Obonai, Toshimasa</creatorcontrib><creatorcontrib>Kaneko, Tetsuji</creatorcontrib><creatorcontrib>Miura, Masaru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Qianzhi</au><au>Morikawa, Yoshihiko</au><au>Akahoshi, Shogo</au><au>Miyata, Koichi</au><au>Sakakibara, Hiroshi</au><au>Matsushima, Takahiro</au><au>Koyama, Yutaro</au><au>Obonai, Toshimasa</au><au>Kaneko, Tetsuji</au><au>Miura, Masaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Follow-Up Duration of Echocardiography in Patients with Kawasaki Disease with No Initial Coronary Aneurysms</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>244</volume><spage>133</spage><epage>138.e1</epage><pages>133-138.e1</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><abstract>To evaluate the optimal duration of echocardiographic follow-up in patients with Kawasaki disease without an initial coronary aneurysm.
In this single-center, retrospective, observational study, we reviewed the results of follow-up echocardiography in children with Kawasaki disease enrolled in the Prospective Observational Study on Stratified Treatment with Immunoglobulin Plus Steroid Efficacy for Kawasaki Disease from a children's hospital. The main enrollment criterion was the absence of coronary aneurysms, defined as a maximum z-score (Zmax) ≥2.5, in the proximal right coronary artery and the proximal left anterior descending artery within 9 days from treatment initiation. The primary outcome was Zmax on follow-up echocardiography at up to 5 years.
Among 386 patients, 106 (27.5%) received prednisolone with intravenous immunoglobulin for first-line therapy, and 57 (14.8%) showed a poor response. Echocardiography at 1 month detected 9 patients with a Zmax ≥2, including 3 (0.8%) with coronary aneurysms requiring additional antithrombotic treatment and observation. Of 7 patients (1.8%) with normal echocardiographic findings at 1 month but a Zmax ≥2 later, 2 were lost to follow-up and 5 experienced spontaneous resolution, but none of the 7 patients required any change in management.
The optimal duration of echocardiographic follow-up may be 1 month in patients with no initial coronary aneurysms and a Zmax <2 at 1 month. Coronary artery abnormalities observed after 1 month are rare and mostly benign in this category of patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34798077</pmid><doi>10.1016/j.jpeds.2021.11.022</doi><orcidid>https://orcid.org/0000-0003-1768-9927</orcidid><orcidid>https://orcid.org/0000-0002-2049-5309</orcidid><orcidid>https://orcid.org/0000-0003-3314-0571</orcidid><orcidid>https://orcid.org/0000-0001-6041-1731</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3476 |
ispartof | The Journal of pediatrics, 2022-05, Vol.244, p.133-138.e1 |
issn | 0022-3476 1097-6833 |
language | eng |
recordid | cdi_proquest_miscellaneous_2600285140 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | American Heart Association Child Coronary Aneurysm - diagnostic imaging Coronary Aneurysm - etiology coronary artery lesion Coronary Vessels - diagnostic imaging Echocardiography Follow-Up Studies Humans Immunoglobulins, Intravenous - therapeutic use Infant Mucocutaneous Lymph Node Syndrome - complications Mucocutaneous Lymph Node Syndrome - diagnostic imaging Mucocutaneous Lymph Node Syndrome - drug therapy Retrospective Studies z-score |
title | Follow-Up Duration of Echocardiography in Patients with Kawasaki Disease with No Initial Coronary Aneurysms |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T19%3A04%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Follow-Up%20Duration%20of%20Echocardiography%20in%20Patients%20with%20Kawasaki%20Disease%20with%20No%20Initial%20Coronary%20Aneurysms&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Wang,%20Qianzhi&rft.date=2022-05-01&rft.volume=244&rft.spage=133&rft.epage=138.e1&rft.pages=133-138.e1&rft.issn=0022-3476&rft.eissn=1097-6833&rft_id=info:doi/10.1016/j.jpeds.2021.11.022&rft_dat=%3Cproquest_cross%3E2600285140%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2600285140&rft_id=info:pmid/34798077&rft_els_id=S0022347621010945&rfr_iscdi=true |